Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients

Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients

Aim: To independently assess the impact of mandatory testing using an extended DPYD variant panel (ToxNav®) and consequent dose adjustment of Capecitabine/5-FU on recorded quantitative toxicity, symptoms of depression, and hospital costs. Methods: We used propensity score matching (PSM) to match 466...

Full description

Bibliographic Details
Main Authors: Chaytor, C. (Author), Hassan, A.B (Author), Koleva-Kolarova, R. (Author), Miah, J. (Author), Rizzo, G. (Author), Solomons, L. (Author), Taylor, H. (Author), Tsiachristas, A. (Author), Vallance, G. (Author), Wordsworth, S. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items